New Standard of Care in Relapsed, Refractory Myeloma?

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

In this video, Antonio Palumbo, MD, discusses results of the CASTOR trial, which studied daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.

Dr. Antonio Palumbo discusses results of the CASTOR trial
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      An interim analysis of the CASTOR trial, which is studying the anti-CD38 monoclonal antibody daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma, found that the three-drug regimen may be the new standard of care in this patient population.

      The data were presented by Antonio Palumbo, MD, chief of the myeloma unit at University of Torino in Italy, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 3–7 in Chicago. Here Dr. Palumbo discusses the results with Cancer Network.

      Recent Videos
      Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
      Spreading Greater CAR T-Cell Therapy Education in the Community Setting
      Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
      Avoiding CAR T-Cell Collection Problems Following Bridging Therapies
      Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
      Academic/Community Collaboration May Help Facilitate CAR T Therapy Access
      A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
      Hybrid Model of CAR T-Cell Therapy May Help Manage Treatment-Related Infections
      A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
      Secondary Malignancies Risk Still in Question Following CAR T-cell Therapy for Lymphoma
      A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
      Study Aims to Address CAR T Accessibility Among Disadvantaged Groups
      Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
      Addressing Challenges in TP53-Mutant Acute Myeloid Leukemia
      Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
      Menin Inhibitor Developments Move Acute Myeloid Leukemia Landscape Forward
      Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
      Advocate Outlines Resources for Chronic Myeloid Leukemia Population
      Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
      Assessing the Future With “Promising” Antibody Drug Conjugates in Breast Cancer
      Related Content
      The combination regimen was well tolerated in JAK inhibitor-naïve myelofibrosis, with instances of thrombocytopenia managed with dose modifications.

      Pelabresib Plus Ruxolitinib Improves Spleen Responses in Myelofibrosis

      Roman Fabbricatore
      March 17th 2025
      Article

      The combination regimen was well tolerated in JAK inhibitor-naïve myelofibrosis, with instances of thrombocytopenia managed with dose modifications.

      A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

      Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

      Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
      October 21st 2024
      Podcast

      A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

      Lenalidomide capsules and dasatinib tablets have received FDA approval through an abbreviated new drug application for various hematologic malignancies.

      Lenalidomide/Dasatinib Receive FDA Approval in Hematologic Malignancies

      Roman Fabbricatore
      March 7th 2025
      Article

      Lenalidomide capsules and dasatinib tablets have received FDA approval through an abbreviated new drug application for various hematologic malignancies.

      Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

      Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

      Rahul Banerjee, MD, FACP;Noopur Raje, MD
      September 2nd 2024
      Podcast

      Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

      Prophylactic defibrotide conferred more ICU admissions and higher mortality among high-risk pediatric patients who underwent prior HSCT.

      Post-HSCT Defibrotide Does Not Reduce Sinusoidal Obstruction Syndrome

      Russ Conroy
      February 14th 2025
      Article

      Prophylactic defibrotide conferred more ICU admissions and higher mortality among high-risk pediatric patients who underwent prior HSCT.

      The analysis saw minimal evidence of increased relapse among patients with hematologic cancers and minimal residual disease vs those without.

      UCBT Yields Excellent Efficacy Outcomes in Hematologic Malignancies

      Roman Fabbricatore
      February 13th 2025
      Article

      The analysis saw minimal evidence of increased relapse among patients with hematologic cancers and minimal residual disease vs those without.